Landos Biopharma is a late clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Our lead product candidate, omilancor (BT-11), is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. In 2021, the Company reported final results from a Phase 2 proof-of-concept trial of omilancor in patients with mild-to-moderate ulcerative colitis (UC) and is preparing to initiate a global pivotal Phase 3 program of omilancor in UC patients. Additionally, Landos initiated a Phase 2 trial of omilancor for the treatment of moderate-to-severe Crohn’s disease (CD) in May 2021.
The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm for autoimmune disease.
Tim M. Mayleben was most recently the President, CEO and Director of Esperion Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of therapies for the treatment of patients with elevated levels of LDL-cholesterol. In this role, he oversaw the development, strategy and commercial product launch of NexletolTM/NexlizetTM, as well as initiated collaborations with key commercial and development partners. Mr. Mayleben has more than two decades of executive leadership experience in the life science industry including as former President, CEO and Director of Vericel Corporation (formerly Aastrom Biosciences, Inc.), former President, COO and Board member of Virtual Radiologics (formerly Nighthawk Radiology Holdings, Inc), and former COO and CFO of the original Esperion Therapeutics, Inc. until its acquisition by Pfizer, Inc. (NYSE: PFE) in 2004. Mr. Mayleben also serves as an Independent Board member of Marinus Pharmaceuticals (NASDAQ: MRNS) and Kaleo, Inc. where he also serves as non-executive Chairman.
Mr. Mayleben earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.
Raquel Hontecillas, Ph.D., has served as our Chief Scientific Officer since our founding in January 2017. She brings 20 years of translational immunology research experience in the biotech industry, with a focus on infectious, autoimmune, and metabolic diseases. She leads efforts aimed at identifying and validating the role of the Lanthionine Synthetase C-Like 2 (LANCL2), NLRX1, PLXDC2 and other immunometabolic pathways as a key therapeutic targets for inflammatory bowel disease (IBD) and other autoimmune diseases. Dr. Hontecillas is the Co-Director of the NIMML Institute, a position she has held since July 2002, and the Chief Scientific Officer of Biotherapeutics, Inc., a position she has held since October 2008. She previously served as a Research Professor of Immunology at Virginia Tech. She co-directed NIH and DOD-funded $68M translational research program in computational and mucosal immunology centered on studying the gastrointestinal immune system. Raquel has published over 250 peer-reviewed publications and has contributed to 30 patents. Dr. Hontecillas holds a degree in Veterinary Medicine from Universidad Complutense University de Madrid, Spain and a Ph.D. in Immunology from Iowa State University.
Jyoti Chauhan is a solutions and result oriented, RAC certified professional who currently serves as Executive Vice President, Clinical and Regulatory Affairs and has held various other positions at Landos since the inception of the organization. She has extensive experience with product development encompassing regulatory strategy, regulatory filings, clinical trials management, regulatory intelligence, and policy analysis. At Landos, she oversees day to day operations, clinical and regulatory affairs to efficiently execute multiple projects in a fast-paced environment. She has successfully created and implemented agile business and technical operating processes for advancement of pipeline assets in various indications. She has been involved with strategy building and operational implementation for the success of the organization in all facets of the business. Ms. Chauhan holds a M.S. in Pharmaceutical Sciences.
Andrew Leber, Ph.D. contributes deep knowledge of immunology, advanced computational modeling, data analytics, AI, and drug development to Landos Biopharma. As the Executive Scientific Director, he is responsible for assessing the therapeutic potential of lead immunoregulatory targets in autoimmune diseases. Dr. Leber’s expertise in immunometabolism helped Landos advance its first-in-class clinical assets for IBD, BT-11 and NX-13, into clinical development. Dr. Leber obtained his B.S. in bioengineering and biomedical engineering from Pennsylvania State University and his Ph.D. in genetics, bioinformatics, and computational biology from Virginia Tech.
Simon Lichtiger, M.D. holds 40 years of experience as a gastroenterologist with a focus in ulcerative colitis and Crohn’s disease. He is a doctor of gastroenterology by trade and was a professor of Gastroenterology and Director of the IBD Division at Columbia University and Clinical Gastroenterologist at Mount Sinai School of Medicine. He has published more than 70 papers in peer-reviewed journals and recently edited a textbook in IBD. Dr. Lichtiger received his medical degree from the NYU School of Medicine.
Nuria Tubau-Juni, Ph.D. brings expertise in translational immunology and metabolism, and has been focused on the identification of novel immunometabolic mechanisms and pathways underlying autoimmune and infectious diseases. Dr. Tubau-Juni is responsible of advancing several drug-based discovery preclinical programs and has helped Landos push its novel assets through the preclinical pipeline and into the clinical development. Her expertise encompasses models of autoimmune disease, in vitro systems, human clinical studies, metabolic assays, bioinformatics, modeling and data analytics. She is also involved in translational and clinical studies of ulcerative colitis and Crohn’s disease. Dr. Tubau-Juni earned her B.S. in Biomedical Sciences from Universitat Autònoma de Barcelona, M.S. in Translational Biomedical Research from Vall d’Hebron Institut de Recerca, and Ph.D. in Genomics, Bioinformatics, and Computational Biology from Virginia Tech.
Jenny has 15 years of experience in accounting and financial systems for both large corporations and small businesses. In her role as Vice President of Finance & Controller at Landos Biopharma, she manages business controller services as well as provides council on how to improve operational efficiencies. Jenny holds a Master’s degree in Accounting with a focus in taxation.